ENHANCED ORAL BIOAVAILABILITY IN ALBINO RABBITS OF LOVASTATIN NANOPARTICLES by Shinde, Anilkumar Jalindar
Shinde et al                JDDT; Special Issue1: "Drug Delivery using Nanomedicine & Nanotechnology                 7 
© 2011-14, JDDT. All Rights Reserved                                                ISSN: 2250-1177                                                CODEN (USA): JDDTAO 
Available online on 25.06.2014 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open access to Pharmaceutical and Medical research 
© 2014, publisher and licensee JDDT, This is an Open Access article which permits unrestricted noncommercial use, provided the original 
work is properly cited 
 
RESEARCH ARTICLE 
ENHANCED ORAL BIOAVAILABILITY IN ALBINO RABBITS OF LOVASTATIN 
NANOPARTICLES  
*Anilkumar J. Shinde, Harinath N. More 
Department of Pharmaceutics, Bharati Vidyapeeth, College of Pharmacy, Kolhapur, India 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Poor solubility is in most cases associated with poor 
bioavailability. The first approach was of limited success 
as clearly demonstrated by the low number of products 
on the market based on such technologies.1,2 A much 
more straight forward way is increasing the dissolution 
velocity by increasing the surface area of the drug 
powder, i.e. micronisation leading to mean particle sizes 
of approximately 3 - 5 μm. However, many of the new 
compounds show such a low solublility that 
micronisation does not lead to a sufficient increase in 
bioavailability after oral administration. Therefore the 
next step taken was nanonisation.3,4 The drug powder is 
transferred to drug nanocrystals or nanoparticles, typical 
sizes are around 200 - 600 nm. However, the most 
convenient dosage form for the patient is a dry product, 
e.g. tablet or capsule. The present work was describes the 
formulation of drug nanoparticles to tablets. Lovastatin is 
a potent, effective lipid lowering agent, insoluble in 
water and its the extensive first-pass effect, with a good 
tolerability profile has systemic bioavailability only 5%. 
For water insoluble drugs with high permeability, drug 
absorption by GIT is limited by drug dissolution rate 
solubility/dissolution are good pointer and major 
contributor to drug bioavailability.5-9  
Nanoparticles have drawn greater attention because of 
their solubilisation and transport properties. Therefore, it 
is very important to devise effective methods to enhance 
the solubility and dissolution rate of drug, consequently 
increasing its bioavailability.10  Limited analytical 
methods have been developed for the determination of 
lovastatin in biological samples by high performance 
liquid chromatography methods. Therefore, the aim of 
the present investigation was to develop a new, sensitive 
HPLC method for the estimation of lovastatin in albino 
rabbits plasma.11-12 The outcome of a study depends upon 
the reliability, reproducibility and sensitivity of the 
analytical methodology employed.  
The objective of the study is to develop a nanoparticle of 
lovastatin and to assess the bioavailability in comparison 
to lovastatin tablets in albino rabbits. 
 
 
 
 
*Corresponding Author: 
Dr. Anilkumar J. Shinde, 
Department of Pharmaceutics,  
Bharati Vidhyapeeth, College of Pharmacy, 
Near chitranagari, Kolhapur - 416013. 
Maharashtra, India. 
Tel: +91 231 2637286;  Fax: +91 231 2638833 
Mobile.no. +91 09823866196; 
Email: ajshinde07@rediffmail.com  
ABSTRACT 
The aim of the study was to compare the single dose oral bioavailability of lovastatin (LV) nanoparticles in albino rabbits. 
Plasma was analyzed for lovastatin using a sensitive, reproducible, accurate and validated RP-HPLC method. Pharmacokinetic 
parameters including AUC, Cmax, Tmax, t1/2, MRT and Kel   were determined from plasma concentration of the formulations. 
The randomly divided into three treatment groups with six animals in each group, as standard I, Standard II and Test. 
Lovastatin pure drug and lovastatin lovastatin marketed formulation were administered to standard group. Lovastatin loaded 
nanoparticles suspension was administered to test group.  The Cmax of LV nanoparticles was found to be 72.28 ±0.158 ng/ml, 
whereas Cmax value for the drug suspension and marketed tablet formulation was found to be 33.10 ± 0.176ng/ml and 40.96 ±  
0.244ng/ml respectively. (P < 0.001) indicating facilitated absorption of LV by nanoparticles. Tmax of lovastatin nanoparticles 
was 2 hrs, whereas for the drug suspension and marketed tablet formulation were 1 h respectively. (P < 0.001). The AUC (0–
∞h) value for the lovastatin nanoparticles, drug suspension and marketed tablet formulation were found to be  301.43 ±0.165 
(ng/ml × h), 73.88 ± 0.210  (ng/ml × h) and   120.51 ± 0.338 (ng/ml × h) respectively. (p < 0.001) The mean residence time 
(MRT) values for the lovastatin nanoparticles, drug suspension and marketed tablet formulation were found to be 1.41 h, 1.35 
h and 1.63 h respectively. (P < 0.001)  The relative bioavailability was found to be significant improvement in bioavailability 
(1.5 fold) as compared with the conventional tablets. 
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MATERIALS AND METHODS 
Lovastatin was a obtained from gift sample from 
Aurobindo Pharmaceutical Ltd., Hydrabad; Chitosan was 
procured from Marine chemicals, Cochin, Sodium 
tripolyphosphate was purchased from Loba chemie, 
Mumbai, dialysis bag (cellophane membrane, molecular 
weight cut off 10000-12000 Da, purchased from Hi-
Media, Mumbai. India. All other reagents and chemicals 
used in this study were of analytical Grade. 
Preparation of Chitosan Nanoparticles  
The Chitosan nanoparticles containing lovastatin were 
prepared by ionotropic gelation method.13-16 Chitosan 
was dissolved in 1% acetic acid solutions at various 
concentrations to obtain (0.1%, 0.2% & 0.3%) and 
adjusted the pH 5-6 with 0.1N sodium hydroxide 
solution. while STPP was dissolved in deionized water at 
various concentrations to obtain 0.1%, 0.15% and 0.20%. 
Lovastatin was dissolved in ethanol/ water mixture (1:1) 
to obtain clear solution. Lovastatin solution was added 
dropwise with syringe needle size 0.45 mm to 40ml 
chitosan solution. The 20ml of STTP solution was added 
dropwise 0.75ml/min under stirring (1000 rpm) at 
ambient temperature to the chitosan solution. The 
formulation was stirred for 30 minutes, so as to remove 
ethanol content. All the formulation was sonicated at 
fixed time for 30 minutes. Nanoparticles were collected 
by centrifugation at 15,000 rpm for a period of 1 h and 
supernatant were discarded. The resultant dispersion was 
dried using a freeze-drying method.17-21 
Characterisation of Nanoparticles 
Lovastatin nanoparticles was characterized for particle 
size, zeta potential and polydispersity index was 
determined by Zetasizer (Malvern, UK),22 percent 
entrapment efficiency, percent process yield, percent 
drug content, In-vitro drug release studies were 
performed in USP Type II dissolution apparatus at 
rotation speed of 50 rpm. The compatibility of drug and 
excipients determined by Fourier Transform Infrared 
Spectroscopy study. The % degree of crystallinity of LV, 
Physical mixture and various batches of nanoparticles 
were calculated by differential scanning calorimetry. 
Detect the crystallinity of the pure drug and the 
nanoparticles formulation, which was performed using a 
Philips PW 3710 x-ray diffractometer. The morphology 
of nanoparticles was examined by using scanning 
electron microscopy (SEM, JSM-6360LV scanning 
microscope Tokyo, Japan) and Transmission electron 
microscopy. The optimized batch of prepared 
nanoparticles was selected for oral bioavailability study 
on albino rabbits.                      
Saturation Solubility Studies 
Accurately weighed 10mg of lovastatin and the 
nanoparticles equivalent to 10 mg of the drug were 
separately introduced into 25ml stoppered conical flasks 
containing 10ml phosphate buffer (pH 7.4). The sealed 
flasks were agitated on a rotary shaker for 24 h at 37°C 
and equilibrated for 2 days. An aliquot was passed 
through 0.45 μm membrane filter and the filtrate was 
suitably diluted and analyzed for drug content on a UV 
spectrophotometer at 243 nm wavelength.      
Determination of lovastatin in albino rabbits blood by 
RP-HPLC
 
Experimental animals  
Eighteen rabbits were used for the bioavailability study. 
All the animals having weight 1.5 to 3.0 kg and 
randomly divided into treatment three groups with six 
animals in each group. Albino rabbits were grouped 
standard I, Standard II and Test. LV suspension and LV 
marketed formulation were administered to standard 
group. LV loaded nanoaprticles suspension was 
administered to test group. Animals had free access to 
food and water ad libitum. The albino rabbits were kept 
under standard conditions in animal house of Bharati 
Vidyapeeth College of Pharmacy, Kolhapur, as per 
guidelines of CPCSEA; approval letter no. BVCPK/ 
CPESEA/ IAEC/ 01/ 17dated Jan. 12, 2011. The 
formulations were provided orally using 23-guage oral 
feeding needle. LV tablet suspended in purified water 
and 1 mg equivalent dose orally administered to 
reference group (RG) rabbits. LV nanoparticles 
formulation 1 mg equivalent dose orally administered to 
treatment group (TG) rabbits. Rabbits were anaesthetized 
using ether. Blood samples were withdrawn from 
marginal ear vein of rabbits at 0.5, 1, 2, 4, 8 and 12 h. 
The plasma was separated and drug content was 
estimated using RPHPLC.23 In this method acetonitrile 
and double distilled water (pH 3) (80:20) with 0.1% 
OPA as mobile phase and RP-HPLC (Jasco PU 2080 
Pump, UV 2075 Detector).  
Determination of lovastatin in albino rabbits blood by 
RP-HPLC 
Linearity study of lovastatin  
Standard working solutions of 1000μg/ml of lovastatin, 
were prepared using mobile phase as a solvent. Required 
volume of solution from standard working solution was 
taken to get final dilutions of required strength for 
calibration curves and made up the volume with mobile 
phase. The HPLC analysis of all aliquots was carried out 
and response factor for each analyte was calculated. 
Preparation of Internal Standard Solution 
Standard stock solution containing simvastatin was 
prepared by dissolving 50 mg of simvastatin in 20 ml of 
mobile phase. It was then sonicated for 10 minutes and 
the final volume of solution was made up to 50 ml with 
mobile phase to get 1000 μg/ml of simvastatin in a 50 ml 
volumetric flask. 
Recovery Studies 
Accuracy of analysis was determined by performing 
recovery studies by spiking different concentrations of 
pure drug in the pre-analyzed laboratory sample 
System Suitability Parameters 
System suitability parameters were analyzed on freshly 
prepared standard stock solutions of lovastatin. All these 
analytes were injected into the chromatographic system 
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under the optimized chromatographic conditions. 
Parameters that were studied to evaluate the suitability of 
the system were number of theoretical plates, calibration 
curve, capacity factor, resolution factor, retention time. 
Processing of Blood samples for HPLC analysis 
All frozen plasma samples were thawed at ambient 
temperature. 200 μl plasma sample was transferred to a 2 
ml polypropylene test tube. The tube was vortex and then 
liquid extraction was carried out with 1 ml of methyl 
tert-butyl ether. Tube was vortexing for 30 sec. and 
centrifuged for 15 min at 4°C at 3000 rpm. The 
supernant was separated and transferred to a clean 
polypropylene test tube and air dried at 40°C. The 
residue was reconstituted with 100 μl of methanol and 
filtered through 0.22 μm syringe filter, then 20 μl volume 
was injected into RP-HPLC. The flow rate was 1 ml/min 
and UV detection was performed at 243 nm. The 
retention time and detection of lovastatin was 
determined.  
Estimation of Pharmacokinetic Parameters 
The pharmacokinetic parameters for lovastatin pure drug 
suspension, marketed formulation and nanoparticles 
dispersion following oral administration were determined 
from plasma concentration data. The total area under the 
concentration-time curve (AUC) from time zero to 
infinity was calculated by the trapezoidal rule method. 
The maximal concentration (Cmax) and the time to 
maximal concentration (tmax) were obtained directly by 
observation. The relative bioavailability is determined, 
when there are no i.v. data, by comparing different 
dosage forms. As with calculation of bioavailability, 
clearance is assumed to be constant. The relative 
bioavailability can be determined from AUC data. The 
pharmacokinetic (PK) parameters were performed by 
non-compartmental analysis. All values are expressed as 
the mean ± SD. All the analysis of data was performed 
using statistical software package Graph pad prism 5 
version. (Graph Pad Software, San Diego,CA, USA), 
using one-way analysis of variance (ANOVA) followed 
by Tukey-Kramer multiple comparison test. Difference 
between two parameters were considered stastically 
significant for P<0.001.  
RESULT AND DISCUSSION 
Characterization of nanoparticles 
The lovastatin loaded nanoparticles by ionotropic 
gelation method found to white in color with 
characteristic odor. Analysis of results indicates that 
particle size range was   200-700 nm shown in figure 1.  
Polydispersity index (PI) of prepared nanoparticles 
batches was found to be in the range 0.5376 to 0.9188. 
Entrapment efficiency of batches under investigation was 
in the range of 94.03 ± 0.025 to 98.85 ± 0.035 %. Zeta 
potential for nanoparticles CL1– CL9 batches were in the 
range of +11.27 ± 0.020 to + 48.50 ± 0.072 shown in 
figure 2. The cumulative percentage drug release of 
lovastatin in Phosphate buffer pH 7.4 medium of CL1- 
CL9, 77.98 ± 0.026 % to 91.06 ±0.026% respectively, 
after 60 min. The drug release follows Hixon crowel and 
first order release kinetics mechanism. The drug content 
of the freeze dried nanoparticles batches were found to 
be in the range of 80.93± 0.569 - 94.87 ± 0.495.  
From FTIR and DSC spectra indicated that there was no 
chemical interaction between lovastatin and chitosan 
used in the formulation hence, can be used in the 
formulation of nanoparticles. The crystallinity of LV 
pure, physical mixture (1:1 lovastatin & CS), lyophilized 
optimized batch were 100%, 83.80% and 31.36% 
respectively. The solubility of lovastatin-loaded 
nanoparticles resulted increase in solubility after 48h 
(237.4 ± 0.041μg/ml) in comparison with lovastatin pure 
drug, i.e increase solubility approximately 5 fold. The 
revealed from the SEM of prepared lovastatin–loaded 
nanoparticles of optimized batch had a spherical shape 
with a relatively uniform size of about 292 nm in 
diameter and no drug crystals were present, depicted in 
figure 3. The morphology of nanoparticles was observed 
by Transmission electron microscopy (TEM) of 
optimized batch, spherical shape and uniform size as 
shown in figure 4.  
 
 
Figure 1: Particle size of nanoparticles of optimized batch 
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Figure 2: Zeta potential of CL4 batch nanoparticles 
 
Figure 3: SEM photomicrograph of optimized batch 
 
 
 
 
 
 
 
 
                              Figure 4: Transmission electron microscopy of CL4 batch  
Figure 4: Transmission electron microscopy of CL4 batch  (125 kx 3 acquire CCD image A & B) 
(125 kx 3 acquire CCD image A & B) 
Validation of method development 
The HPLC chromatogram of lovastatin, overlain spectra of HPLC chromatogram of lovastatin and calibration curve of 
lovastatin by HPLC are given in figure 5, 6 respectively. Different parameters of calibration curve such as slope, 
intercept and coefficient of correlation obtained are given in table 1. 
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Figure 5:  HPLC chromatogram of lovastatin 
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Figure 6: Calibration curve of lovastatin by HPLC 
Table 1: Various constant for calibration curves in HPLC 
Regression Equation Data 
Y = A + B*C 
Simvastatin Lovastatin 
Slope (B) 2037.28 68371.95 
Intercept (A) 13076.77 13562.00 
Correlation coefficient (R) 0.9910 0.98175 
Where C is the concentration in µg/ml and Y is the unit of response factor. 
Linearity study of lovastatin  
The calibration curve for lovastatin was found to be 
linear in concentration range of 50μg/ml to 250μg/ml. 
The result of laboratory sample assay is reported in table 
2. Results of recovery studies indicating that the method 
is rapid, accurate and reproducible are shown in table 3. 
System Suitability Parameters All these analytes were 
injected into the chromatographic system under the 
optimized chromatographic conditions shown in table 4. 
The limit of detection and limit of quantitation given in 
table 5. 
 
Table 2: Results of Analysis of Laboratory Sample 
Analyte 
% Concentration estimated* 
(Mean ± S.D.) 
% R.S.D. 
Simvastatin 99.13 ± 1.6517 0.8754 
Lovastatin 99.17 ±1.9255 0.8351 
* Average of six determinations. 
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Table 3: Results of Recovery Studies 
Analyte % Recovery estimated*(Mean ± S.D.) %R.S.D. 
Simvastatin 99.05 ± 1.13586 0.9632 
Lovastatin 99.59 ±1.2459 0.4173 
* Average of six determinations. 
Table 4: System Suitability Parameters 
Sr. No. Parameters Simvastatin Lovastatin 
1. Retention Time in minutes (α) 9.073 7.388 
2. Number of Theoretical plates 9021.26 7642.3 
3. Asymmetry 2.161 2.015 
4. Calibration Curve (μg/ml) 10-250 0.2-25.6 
5. Capacity factor (k’) 902.35 738 
6. Resolution (R
S
) 4.52 2.86 
 
Table 5: Limit of Detection and Limit of Quantitation 
Sr.No. Analyte Simvastatin Lovastatin 
     1. Limit of Detection (μg/ ml)  0.045 0.031 
     2. Limit of Quantitation ( μg/ ml) 0.035 0.094 
 
The retention time of HPLC chromatogram was 7.360 
min. Pharmacokinetic parameters of LV nanoparticles, 
LV pure and LV marketed tablets were compared in 
albino rabbits. The bioavailability study was performed 
with objective of estimating lovastatin after oral 
administration. By comparison of standard and test group 
it was observed that, Cmax of LV nanoparticles was 
found to be 72.28 ±0.158 ng/ml, whereas Cmax value for 
the drug suspension and marketed tablet formulation was 
found to be 33.10 ± 0.176ng/ml and 40.96 ±  0.244ng/ml 
respectively, indicating facilitated absorption of LV by 
nanoparticles shown in figure 7. After oral 
administration, lovastatin nanoparticles were absorbed 
much slower than lovastatin pure and marketed 
formulation. Tmax of lovastatin nanoparticles was 2 hrs, 
whereas for the drug suspension and marketed tablet 
formulation were 1 h respectively. (P < 0.001) 
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Figure 7: In-vivo release profile of pure drug, marketed tablet and CL4 batch in plasma 
AUC (0–∞ h) value for the lovastatin nanoparticles, drug 
suspension and marketed tablet formulation were found 
to be 301.43±0.165 (ng/ml × h), 73.88 ± 0.210 (ng/ml × 
h) and   120.51 ± 0.338 (ng/ml × h) respectively. (P < 
0.001) The elimination rate constant (Ke) value for the 
lovastatin nanoparticles, drug suspension and marketed 
tablet formulation were found to be 0.703, 0.735 and 
0.610 respectively.(P < 0.001) The elimination half life 
(t1/2) for the lovastatin nanoparticles, drug suspension 
and marketed tablet formulation were found to be 0.98 h, 
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0.94 h and 1.136 h respectively.(P < 0.001) The mean 
residence time (MRT) values for the lovastatin 
nanoparticles, drug suspension and marketed tablet 
formulation were found to be 1.41 h, 1.35 h and 1.63 h 
respectively. (P < 0.001)  
The relative bioavailability was increased as compared to 
oral control group Standard I & II, it was found that 
relative bioavailability was 407.9 % and 250.12 % 
respectively. (P < 0.001) Pharmacokinetic data for pure 
drug, marketed formulation & optimized batch 
formulation in plasma given in table 6. The in vivo study 
results reveals that LV nanoparticles show better 
bioavailability than drug suspension and marketed 
formulation. The above results indicated that the LV 
nanoparticles have the potential to be used to increase the 
oral bioavailability of highly lipophilic drugs. 
 
Table 6: Pharmacokinetic data for Pure drug, Marketed formulation & optimized batch formulation in plasma 
Sr. 
No. 
Pharmacokinetic 
parameters 
Pure Drug Marketed 
formulation 
Nanoparticles 
CL4 batch 
1. C max (ng/ml) 33.10 ± 0.065 40.96 ± 0.075 72.28 ± 0.198 
2. T max (h) 1 1 2 
3. AUC (ng/ml × h) 
         (0- 8 h ) 
65.86± 0.29 107.56 ± 0.337 252.85± 0.134 
4. AUC (ng/ml × h) 
         (0 - ∞ h ) 
73.88±0.210 
 
120.51±0.338 301.43±0.165 
5. Ke (h) 0.735 0.610 0.703 
6. t1/2 (h) 0.940 1.136 0.980 
7. MRT (h) 1.35 1.63 1.41 
8. Fr (%) -- -- 407.99 * 
250.12** 
* Calculated on AUC (0- ∞ h) with lovastatin suspension (Std. I)  as reference 
** Calculated on AUC(0- ∞ h) with lovastatin marketed tablet (Std. II) as reference 
 
CONCLUSION 
In vivo studies on rabbits revealed overall increase in 
bioavailability of the drug upon oral administration of 
nanoparticles formulation as compared with pure 
suspension and marketed formulation. The experimental 
findings collectively support that prepared nanoparticles 
had the potential to enhance solubility, dissolution rate 
correlates with faster oral absorption and bioavailability 
of poorly water soluble drugs. Lovastatin nanoparticles 
formulation showed a significant improvement in 
bioavailability as compared with the conventional 
tablets. As a result, nanoparticles could be a promising 
delivery system to enhance the oral bioavailability of 
highly lipophilic drug of lovastatin. 
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